Dual activated NIR-II fluorescence and photoacoustic imaging-guided cancer chemo-radiotherapy using hybrid plasmonic-flu
- PDF / 3,858,178 Bytes
- 10 Pages / 612 x 808 pts Page_size
- 112 Downloads / 193 Views
Dual activated NIR-II fluorescence and photoacoustic imagingguided cancer chemo-radiotherapy using hybrid plasmonicfluorescent assemblies Tao Chen, Lichao Su, Xiaoguang Ge, Wenmin Zhang, Qingqing Li, Xuan Zhang, Jiamin Ye, Lisen Lin, Jibin Song (), and Huanghao Yang () MOE Key Laboratory for Analytical Science of Food Safety and Biology, College of Chemistry, Fuzhou University, Fuzhou 350116, China © Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2020 Received: 21 June 2020 / Revised: 19 July 2020/ Accepted: 20 July 2020
ABSTRACT Multimodal imaging in the second near-infrared window (NIR-II) guided cancer therapy is a highly precise and efficient cancer theranostic strategy. However, it is still a challenge to develop activated NIR-II optical imaging and therapy agents. In this study, we develop a pH-responsive hybrid plasmonic-fluorescent vesicle by self-assembly of amphiphilic plasmonic nanogapped gold nanorod (AuNNR) and fluorescent down-conversion nanoparticles (DCNP) (AuNNR-DCNP Ve), showing remarkable and activated NIR-II fluorescence (FL)/NIR-II photoacoustic (PA) imaging performances. The hybrid vesicle also exhibited superior loading capacity of doxorubicin as a superior drug carrier and efficient radiosensitizer for X-ray-induced radiotherapy. Interestingly, the accumulated hybrid AuNNR-DCNP Ve in the tumor resulted in a recovery of NIR-II FL imaging signal and a variation in NIR-II PA imaging signal. Dual activated NIR-II PA and FL imaging of the hybrid vesicle could trace drug release and precisely guided cancer radiotherapy to ultimately reduce the side effects to healthy tissue.
KEYWORDS radiotherapy, second near-infrared window (NIR-II), fluorescence imaging, photoacoustic imaging, plasmonic gold nanovesicle
1
Introduction
Cancer remains a significant global challenge to human health [1–6]. Although a large number of potential new cancer treatments have been explored, only limited success has been achieved due to the heterogeneity and complexity of tumors [7–10]. To fight cancer, innovative intelligent nanoplatforms with therapeutic and diagnostic capabilities are highly warranted [11–13]. Theranostics, a novel concept of simultaneous diagnosis and treatment technology, provide a practicable strategy for real-time monitoring and reflect the effects of treatment, and optimize the efficiency and safety of treatment strategies [14–17]. The treatment technology simplifies the entire drug development process and saves a significant amount of money for the entire medical system [18–20]. Therefore, a diagnostic probe that combines diagnostic imaging and therapeutic functions would be an excellent alternative to contrast agents and cancer treatment strategies rather than traditional single diagnostic functions [21–23]. Nanoparticle-based diagnostic probes have high encapsulation ability to achieve the goal of the cancer diagnosis and treatment, and can cover various reagents and drugs with different diagnostic and therapeutic functions [24–26]. Real-time and accura
Data Loading...
